Executive Chairman David Schlanger Sells 162,906 Shares of Progyny Inc (PGNY)
On December 22, 2023, Executive Chairman David Schlanger sold 162,906 shares of Progyny Inc (NASDAQ:PGNY), as reported in a recent SEC Filing. Following this transaction, the insider has sold a total of 1,163,969 shares over the past year and has not made any share purchases in the same period.
Progyny Inc is a company that specializes in fertility and family building benefits solutions in the United States. It offers employer-sponsored fertility benefits for employees and their partners who are seeking to start a family. Progyny's services include access to a network of fertility specialists, treatment management, and pharmacy benefits.
The insider transaction history for Progyny Inc shows a pattern of insider selling, with 39 insider sells and no insider buys over the past year.
On the valuation front, Progyny Inc's shares were trading at $37.87 on the day of the insider's recent sale, resulting in a market cap of $3.676 billion. The price-earnings ratio stands at 73.77, which is above the industry median of 26.235 but below the company's historical median price-earnings ratio.
According to the GF Value, with a price of $37.87 and a GuruFocus Value of $80.04, Progyny Inc has a price-to-GF-Value ratio of 0.47, indicating that the stock is Significantly Undervalued.
The GF Value is an intrinsic value estimate that takes into account historical trading multiples, a GuruFocus adjustment factor based on the company's past returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
